Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: Results from the TEMPO 3:4 trial

Olivier Devuyst, Arlene B. Chapman, Ron T. Gansevoort, Eiji Higashihara, Ronald D. Perrone, Vicente E. Torres, Jaime D. Blais, Wen Zhou, John Ouyang, Frank S. Czerwiec

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: Results from the TEMPO 3:4 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences